Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,663 across all filing types
Latest filing 2025-12-23 Share Issue/Capital Cha…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - AVR 6 pages 19.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance and conversion of unquoted securities, including dates, numbers of securities issued, and details about key management personnel involved. It is a formal notification related to changes in the company's capital structure, specifically the issuance and conversion of securities. This matches the definition of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings. The document is about the issuance and conversion of securities, not an annual report, earnings release, or management discussion. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-12-23 English
Application for quotation of securities - AVR 6 pages 19.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of securities resulting from options exercised or convertible securities converted, including specifics about the number of securities, issue dates, and whether they are part of an employee incentive scheme. The document is focused on the announcement of new securities to be quoted on the exchange rather than a financial report or detailed analysis. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2025-12-23 English
FORM 4
Director's Dealing
2025-12-19 English
FORM 4
Director's Dealing
2025-12-19 English
FORM 4
Director's Dealing
2025-12-19 English
FORM 4
Director's Dealing
2025-12-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.